Not found

Mauro Ferrari, PhD

Ernest Cockrell, Jr. Presidential Distinguished Chair, President & CEO, Research Institute
Director & Professor of Nanomedicine, Institute for Academic Medicine
Executive Vice President, Houston Methodist
Senior Associate Dean and Professor of Medicine, Weill Cornell Medical College


Research Lab


mferrari@houstonmethodist.org
Biography

Mauro Ferrari, PhD, is the Executive Vice President of Houston Methodist and the President and CEO of the Houston Methodist Research Institute where he is the Ernest Cockrell Jr. Presidential Distinguished Chair. As the Director of the Houston Methodist Institute for Academic Medicine, Ferrari oversees all research and education programs at Houston Methodist, over 1,200 research employees and credentialed clinicians executing more than 800 clinical protocols. He also serves as the Senior Associate Dean of the Weill Cornell Medical College, the primary academic affiliate of Houston Methodist and holds Adjunct and Honorary Professorships at many universities around the world.

Ferrari is the founder of biomedical nano/micro-technology, especially in their applications to drug delivery, cell transplantation, implantable bioreactors, and other innovative therapeutic modalities. Dr. Ferrari served as special expert on nanotechnology at the National Cancer Institute in 2003-2005, providing leadership for the formulation, refinement, and approval of the NCI's Alliance for Nanotechnology in Cancer, currently the world's largest program in medical nanotechnology.

He has to his credit more than 350 publications, including seven books and is the inventor of 30 issued patents in the US and Europe. Throughout his academic career, he has supervised trainees and students who have gone on to senior faculty positions at premier universities like Oxford, Massachusetts Institute of Technology (MIT), University of California Berkeley, University of California San Francisco, Duke University, University of Washington, and Ohio State University. Dr. Ferrari's degrees are in Mathematics (Padova, Italy), and Mechanical Engineering (M.S., & Ph.D., U.C. Berkeley).

His seminal contributions to the field of biomedical nanotechnology have been recognized through numerous awards and accolades, including: Founders Award - Controlled Release Society, the Wallace H. Coulter Award for Biomedical Innovation and Entrepreneurship, the ETH Zürich Stodola Medal, Blaise Pascal Medal in Biomedical Engineering - European Academy of Sciences, and the Shannon Director's Award of the National Institutes of Health. Dr. Ferrari is a Fellow of the American Society of Mechanical Engineers, American Academy for the Advancement of Science and American Institute for Medical and Biological Engineering. He also holds honorary doctorates in Electrical Engineering and Biotechnology from the University of Palermo and the University of Naples “Federico II”, respectively.

His career research and development portfolio totals over $50 million, including support from the NCI, NIH, DoD, NASA, NSF, DARPA, DoE, the state of Texas, the state of Ohio, the Ohio State University, and several private enterprises. He began his academic career at the University of California, Berkeley, where he tenured in Material Science, Civil Engineering, and Bioengineering. Upon recruitment to the Ohio State University, he served as the Edgar Hendrickson Professor of Biomedical Engineering, Professor of Internal Medicine, Mechanical Engineering and Materials Science. He was also the Associate Vice President, Health Sciences Technology and Commercialization, Associate Director of the Dorothy M. Davis Heart and Lung Research Institute and Director of the Biomedical Engineering Center. Upon recruitment to Houston, he served as professor and chair of the nanomedicine department at the University of Texas Health Science Center.

Description of Research

Nanomedicine for oncology, traumatic injury, cardiovascular disease, infectious pathologies, and diabetes
Nanofluidics
Biomedical Microtechnology (BioMEMS)
Drug delivery
Proteomics and peptidomics for early detection and therapeutic monitoring
Cell transplantation, regenerative medicine, and tissue engineering
Biosensors and bioseparation technology
Multiscale discrete/continuum mechanics and biomechanics
Bioethics

Areas Of Expertise

Nanomedicine Nanofluidics Cancer Drug delivery Biomedical microtechnology (BioMEMS)
Education & Training

Dottore, Universita' di Padova
PhD, University of California Berkeley
Publications

Unexpected behaviors in molecular transport through size-controlled nanochannels down to the ultra-nanoscale
Bruno, G, Di Trani, N, Hood, RL, Zabre, E, Filgueira, CS, Canavese, G, Jain, P, Smith, Z, Demarchi, D, Hosali, S, Pimpinelli, A, Ferrari, M & Grattoni, A 2018, Nature Communications, vol 9, no. 1, 1682. DOI: 10.1038/s41467-018-04133-8

Correction function for accuracy improvement of the Composite Smeared Finite Element for diffusive transport in biological tissue systems
Milosevic, M, Simic, V, Milicevic, B, Koay, EJ, Ferrari, M, Ziemys, A & Kojic, M 2018, Computer Methods in Applied Mechanics and Engineering, vol 338, pp. 97-116. DOI: 10.1016/j.cma.2018.04.012

DNA Thioaptamer with Homing Specificity to Lymphoma Bone Marrow Involvement
Mai, J, Li, X, Zhang, G, Huang, Y, Xu, R, Shen, Q, Lokesh, GL, Thiviyanathan, V, Chen, L, Liu, H, Zu, Y, Ma, X, Volk, DE, Gorenstein, DG, Ferrari, M & Shen, H 2018, Molecular Pharmaceutics, vol 15, no. 5, pp. 1814-1825. DOI: 10.1021/acs.molpharmaceut.7b01169

Inflammation-targeted vascular nanomedicine
Cooke, JP & Ferrari, M 2018, Nature Biomedical Engineering, vol 2, no. 5, pp. 269-270. DOI: 10.1038/s41551-018-0241-y

SMAD4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy
Wang, F, Xia, X, Yang, C, Shen, J, Mai, J, Kim, H-C, Kirui, D, Kang, Y, Fleming, JB, Koay, EJ, Mitra, S, Ferrari, M & Shen, H 2018, Clinical Cancer Research. DOI: 10.1158/1078-0432.CCR-17-3435

Harnessing and Optimizing the Interplay between Immunotherapy and Radiotherapy to Improve Survival Outcomes
Mujoo, K, Hunt, CR, Pandita, RK, Ferrari, M, Krishnan, S, Cooke, JP, Hahn, S & Pandita, TK 2018, Molecular Cancer Research. DOI: 10.1158/1541-7786.MCR-17-0743

Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma
Zhu, M, Ding, X, Zhao, R, Liu, X, Shen, H, Cai, C, Ferrari, M, Wang, HY & Wang, RF 2018, Journal of Controlled Release, vol 272, pp. 72-82. DOI: 10.1016/j.jconrel.2018.01.004

Polymer Functionalization of Isolated Mitochondria for Cellular Transplantation and Metabolic Phenotype Alteration
Wu, S, Zhang, A, Li, S, Chatterjee, S, Qi, R, Segura-Ibarra, V, Ferrari, M, Gupte, A, Blanco, E & Hamilton, DJ 2018, Advanced Science, pp. 1700530-n/a. DOI: 10.1002/advs.201700530

Polymer Functionalization of Isolated Mitochondria for Cellular Transplantation and Metabolic Phenotype Alteration
Wu, S, Zhang, A, Li, S, Chatterjee, S, Qi, R, Segura-Ibarra, V, Ferrari, M, Gupte, A, Blanco, E & Hamilton, DJ 2018, Advanced Science, pp. 1700530-n/a. DOI: 10.1002/advs.201700530

A novel DNA aptamer for dual targeting of polymorphonuclear myeloid-derived suppressor cells and tumor cells
Liu, H, Mai, J, Shen, J, Wolfram, J, Li, Z, Zhang, G, Xu, R, Li, Y, Mu, C, Zu, Y, Li, X, Lokesh, GL, Thiviyanathan, V, Volk, DE, Gorenstein, DG, Ferrari, M, Hu, Z & Shen, H 2018, Theranostics, vol 8, no. 1, pp. 31-44. DOI: 10.7150/thno.21342

Nanomedicine, an emerging therapeutic strategy for oral cancer therapy
Marcazzan, S, Varoni, EM, Blanco, E, Lodi, G & Ferrari, M 2018, Oral Oncology, vol 76, pp. 1-7. DOI: 10.1016/j.oraloncology.2017.11.014

Implementation of Transitional Strategic Plan at an Academic Medical Center
MacCorkle-Chosnek, R, Ferrari, M & Bass, BL 2018, Academic Medicine.

Transport Barriers and Oncophysics in Cancer Treatment
Nizzero, S, Ziemys, A & Ferrari, M 2018, Trends in Cancer. DOI: 10.1016/j.trecan.2018.02.008

Cell encapsulation: Overcoming barriers in cell transplantation in diabetes and beyond
Farina, M, Alexander, JF, Thekkedath, U, Ferrari, M & Grattoni, A 2018, Advanced Drug Delivery Reviews. DOI: 10.1016/j.addr.2018.04.018

Chloroquine and nanoparticle drug delivery: A promising combination
Pelt, J, Busatto, S, Ferrari, M, Thompson, EA, Mody, K & Wolfram, J 2018, Pharmacology and Therapeutics. DOI: 10.1016/j.pharmthera.2018.06.007

Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity
Wu, X, Hu, Z, Nizzero, S, Zhang, G, Ramirez, MR, Shi, C, Zhou, J, Ferrari, M & Shen, H 2017, Journal of Controlled Release, vol 268, pp. 92-101. DOI: 10.1016/j.jconrel.2017.10.012

Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumoral immunity
Shen, H, Xia, X & Ferrari, M 2017, , Patent No. AU2016243027, IPC No. A61K 39/ 12 A I.

A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery
Wolfram, J, Nizzero, S, Liu, H, Li, F, Zhang, G, Li, Z, Shen, H, Blanco, E & Ferrari, M 2017, Scientific Reports, vol 7, no. 1, pp. 13738. DOI: 10.1038/s41598-017-14221-2

Contribution of Kupffer cells to liposome accumulation in the liver
Samuelsson, E, Shen, H, Blanco, E, Ferrari, M & Wolfram, J 2017, Colloids and Surfaces B: Biointerfaces, vol 158, pp. 356-362. DOI: 10.1016/j.colsurfb.2017.07.014

Nanoparticles administered intrapericardially enhance payload myocardial distribution and retention
Segura-Ibarra, V, Cara, FE, Wu, S, Iruegas-Nunez, DA, Wang, S, Ferrari, M, Ziemys, A, Valderrabano, M & Blanco, E 2017, Journal of Controlled Release, vol 262, pp. 18-27. DOI: 10.1016/j.jconrel.2017.07.012